Lean Times for Obesity Treatment

Author：

ISSN： 1537-1328

Source： Pharmaceutical Innovation, Vol.11, Iss.5, 2002-08, pp. : 21-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rare Genetic Diseases with Human Lean and/or Starvation Phenotype Open New Avenues for Obesity and Type II Diabetes Treatment

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 13, 2013-01 ,pp. : 1093-1098

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of lorcaserin for the treatment of obesity

By Berlie Helen D

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1053-1059

Informa Healthcare

Access to resources Recommend Favorite

Pharmacological Approaches for the Treatment of Obesity

By Fernández-López J-A.

Drugs, Vol. 62, Iss. 6, 2002-01 ,pp. : 915-944

Adis International

Access to resources Recommend Favorite

Orlistat in the treatment of obesity

By Ballinger A.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 841-847

Informa Healthcare

Access to resources Recommend Favorite

Orexins and the treatment of obesity

By Smart D. Haynes A.C. Williams G. Arch J.R.S.

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 199-212

Elsevier

Access to resources Recommend Favorite